Genetic and environmental factors seem to interact and influence both the onset and the course of obsessive--compulsive disorder (OCD), but the role of glutamate transporter variants (SLC1A1) in pharmacological resistance is not known. We aimed to assess whether genetic variants in SLC1A1 and life stress at onset of the disorder interact and modulate pharmacological resistance in OCD. A single-marker association study of several single-nucleotide polymorphisms in the SLC1A1 genomic region was performed in a sample of 238 OCD patients. For the most strongly associated SNP (rs3087879), one copy of the risk allele increased the probability of higher treatment resistance (odds ratio ¼ 2.42; 95% confidence interval ¼ 1.39--4.21; P ¼ 0.0018), but only in OCD patients without life stress at onset of the disorder. These results suggest a gene-by-environment interaction effect on treatment resistance in OCD and strengthen the existing evidence of the role of the glutamatergic system in the phenomenology of OCD.
INTRODUCTION
Obsessive--compulsive disorder (OCD) is a chronic, disabling anxiety disorder estimated to affect 1--3% of the population. 1, 2 As in many other psychiatric conditions, it has been suggested that genetic and environmental factors interact and influence both the onset and course of the disorder. 3 Family, twin and segregation analysis studies have provided strong evidence for the influence of genetic factors in OCD, 3, 4 especially in early-onset OCD, in which between 47 and 58% of OC behavior is explained by genetic factors. 5 In adults, twin studies have indicated a more modest contribution of genetic factors, 6 and the remaining variance seems to be explained more by environmental factors.
Antidepressant drug response is influenced by the cumulative effect of genetic variations and clinical features, which contribute similar effects to the prediction of treatment outcome. 7 Exploring the pharmacogenetics of OCD is currently a major challenge, because rates of successful treatment outcome are relatively low. 8 Current hypotheses focus on the serotonin (5-HT) system, on the basis of the effectiveness of serotonin reuptake inhibitors (SRIs) in alleviating symptoms of patients with OCD. Very few studies have assessed the role of candidate genes in treatment response in OCD, 9, 10 and those available focus mainly on the components of the serotonin pathway (transporter and receptors), with inconclusive results. 9, 11, 12 The limited effectiveness of SRIs suggests the critical involvement of other neurotransmitter systems.
The evidence for the role of the glutamatergic system in OCD is growing. The only positive association with OCD that has been reliably replicated by different groups is the glutamate transporter gene SLC1A1, 13--18 although one negative study has also been published. 19 With regard to other genes or regions, and as is often the case in association studies performed in psychiatric disorders, the discrepancies between the results might be attributed to the underlying phenotypic and genetic heterogeneity, or to the possibility of gene--gene and gene--environment interactions. 20 Neuroimaging and animal studies have also implicated a glutamatergic synaptic dysfunction within the cortico-striatalthalamo-cortical brain circuit in the etiology of OCD (reviewed in Ting and Feng 21 ). Rosenberg et al. 22 found that glutamatergic concentrations in the caudate nucleus decreased after an adequate 12-week paroxetine trial, in parallel with the improvement in OCD symptom severity. A predictive role of glutamatergic concentrations in the anterior cingulate cortex for obsessive--compulsive symptom severity has also been reported. 23 Furthermore, animal studies have shown that 5-HT exerts a very complex modulatory control over glutamate-mediated transmission, involving many subtypes of 5-HT receptors. 24 Following this line of reasoning, some authors have proposed that the glutamatergic system is the one most involved in OCD pathophysiology, and that serotonergic and dopaminergic alterations in OCD are secondary to the glutamatergic alterations. 25 This new perspective complements the earlier focus on monoaminergic neurotransmission in the pathophysiology of OCD. Accordingly, it is plausible that the beneficial clinical effects of SRIs may be mediated by their influence on the glutamatergic system. Hence, several pharmacological studies have used glutamatergic agents such as riluzole and memantine in treatment-resistant OCD patients, and have achieved clinical improvements when used as augmentation strategies in children and adults. 26--28 Although no environmentally influenced OCD subtype has been defined, there is considerable support in the literature for the notion that the disease is a 'stress-sensitive' condition. 29 Stressful life events (SLEs) have been implicated in the onset of the disorder in both children 30 and adults, 31, 32 and have been associated with phenomenological differences in symptom severity 33 and symptom dimensions. 34, 35 SLEs have also been reported to play a minor role as precipitating factors in the onset of familial subtypes of OCD than in subtypes without a familial component. 34--37 A plausible hypothesis would be that distinct pathophysiological mechanisms underlie familial subtypes of the disorder, suggesting a greater genetic component in these cases and a lower influence of environmental factors. 4, 38 In view of all this evidence, we hypothesized that genetic variants in the SLC1A1 gene and the presence of an SLE at onset of OCD interact to influence pharmacological treatment outcome in OCD. To test the hypothesis, we performed a single-marker association study of seven single-nucleotide polymorphism (SNPs) located in the SLC1A1 genomic region in a sample of 238 OCD patients, and performed a stratified analysis based on the presence or absence of an SLE preceding the onset of the disease.
MATERIALS AND METHODS

Sample collection and procedures
The sample comprised 248 outpatients (129 males and 119 females) meeting DSM-IV (Diagnostic and Statistical Manual of Mental DisordersFourth Edition) criteria for OCD and who were consecutively recruited at the OCD Clinic of Bellvitge University Hospital (Barcelona, Spain) between 2003 and 2010. All were Spanish Caucasian subjects referred for clinical treatment from a variety of sources, and all were directly interviewed by two trained psychiatrists (PA and CS) with extensive clinical experience in OCD. To be included in the study, patients had to meet DSM-IV criteria for the disorder 39 lasting at least 1 year. The Structured Clinical Interview for DSM-IV Axis I Disorders-Clinician Version (SCID-CV) 40 was used to confirm the diagnosis. Comorbidity with other DSM-IV Axis I disorders was not considered an exclusion criterion if OCD was believed to be the primary diagnosis (taking into account the severity and functional interference of specific symptoms). Exclusion criteria were: (1) a lifetime history of psychotic disorders; (2) mental retardation; (3) a neurological disease other than a tic disorder; (4) current psychoactive substance abuse, other than tobacco consumption; (5) age under 18 or over 65 years; or (6) refusal to participate. Ten patients were omitted on these grounds. Written informed consent was obtained from all subjects after a full description of the study. This study was performed in accordance with the World Medical Association's Declaration of Helsinki and approved by the institution's ethical committees (Bellvitge Hospital, CEIC Ciutat Sanitària i Universitària de Bellvitge).
Clinical assessment
All subjects completed a semistructured interview that recorded clinical and sociodemographic data, as well as medical information and clinical OCD characteristics such as age at onset, personal history of Tourette's disorder or other tic disorder and comorbidity. Age at onset of OCD was defined as the age when symptoms became a significant source of distress and interfered with the patient's social functioning. Family history of OCD in first-and second-degree relatives was coded as present or absent according to the Family History Research Diagnostic Criteria. 41 Relatives were considered to be affected if they had been formally diagnosed by a psychiatrist, had a history of psychiatric hospitalization or had taken diagnosis-specific medication.
The severity of the obsessive--compulsive and depressive symptoms was assessed through the clinician-administered version of the Yale--Brown Obsessive--Compulsive Scale (Y-BOCS) 42 and the 21-item Hamilton Depression Rating Scale (HDRS), 43 respectively. Lifetime presence of obsessive--compulsive symptoms was assessed by the Y-BOCS Symptom Checklist. 42 The symptoms were then recoded into dichotomous (presence/absence) variables representing the four-factor symptom structure for obsessive--compulsive symptoms recently recommended by a meta-analysis conducted by Bloch et al.:
44 (1) factor 1 (aggressive, sexual, religious and somatic obsessions; checking compulsions); (2) factor 2 (symmetry obsessions; repeating, counting and ordering compulsions); (3) factor 3 (contamination obsessions, washing compulsions); and (4) factor 4 (hoarding obsessions and compulsions). The categorization was not mutually exclusive; patients could score in one or more symptom dimension.
Treatment history assessment. As a highly specialized OCD treatment center, we carefully assess treatment-resistance level at the time of admission to our OCD unit. Previous adequate medication trials completed and clinical response of patients are fully investigated. Pharmacological resistance level is recorded, taking into account standardized measurements of therapeutic effects according to partial or nonresponse to trials lasting more than 12 weeks of at least moderate doses of SRIs, following the recommended guidelines for OCD 45 (that is, clomipramine 150 mg day À1 , fluoxetine 40 mg day À1 , sertraline 100 mg day À1 , paroxetine 40 mg day À1 , fluvoxamine 200 mg day À1 and citalopram 40 mg day À1 ). The variable is represented by seven successive steps including different drugs or combinations of drugs. Although not exactly the same, the ordering of levels of nonresponse in our protocol is in agreement with the operational criteria proposed by Pallanti et al. 46, 47 The stages are defined according to the clinical evaluation of the subjective and symptomatic percentage of amelioration in the patient's own context of living (this would coincide with a Y-BOCS reduction of at least 35% compared with previous treatment). In order to simplify the analyses and to reduce the level of stratification of the sample, in this study all seven resistance levels were grouped into three categories: (1) low resistance (levels 1--3: selective serotonin reuptake inhibitor (SSRI) strategies); (2) medium resistance (level 4: clomipramine treatment); and (3) high resistance (levels 5--7: antipsychotic augmentation strategies, combinations of SRIs or the use of other classes of antidepressants including monoamine oxidase inhibitors). This recoding of the resistance levels is described in Table 1 .
Life stress assessment. Life events at onset of OCD were assessed through a face-to-face direct interview as described elsewhere. 35 Patients without evidence of any SLE during the year before disease onset were considered as non-SLE-preceded OCD probands. Patients who reported an SLE were assigned to the SLE-preceded OCD group. The Paykel Scale of Stressful Life Events 48 was then used to check whether the event identified fitted any of the 61 events on the list, as described in previous studies. 34, 35, 49 SNP selection and genotyping SLC1A1, located on chromosome 9p24, covers a genomic region of 97.03 kb (RefSeq: NM_004170) and contains 12 exons that code for the neuronal and epithelial glutamate transporter.
We selected nine SNPs located in SLC1A1 that have been reported to be associated with OCD in the literature. 13, 14 SNPs were genotyped using Illumina's VeraCode technology (Illumina, San Diego, CA, USA) in accordance with the manufacturer's protocols. Briefly, SNPs that passed the company design rules for the development of good assays were selected to design customized multiplexed beads for further genotyping. The assays developed for the VeraCode beads were detected by Illumina's BeadXpress Reader System and data analysis was performed using Illumina's BeadStudio software (Illumina). The highthroughput genotyping assays were performed at the CeGen genotyping facilities in the Barcelona Node (Centro Nacional de Genotipado, Barcelona, Spain; http://www.cegen.org).
Genotyping for population admixture. The sample studied had been previously genotyped for population admixture with anonymous unlinked SNPs and did not show population stratification (see Alonso et al. 50 for a detailed description).
Statistical analysis
For statistical analysis, we selected SNPs with a minimum genotyping rate of 95%, and in Hardy--Weinberg equilibrium (P40.05); seven of the nine initial SNPs were finally included in the analysis. The overall description of each polymorphism is shown in Table 2 . To test the hypothesis of an association between genotypes and pharmacological resistance level as the dependent variable, we used multivariate methods based on ordinal logistic regression analyses, which allowed us to incorporate the ordinal nature of the dependent variable. We analyzed each polymorphism under an additive inheritance model adjusting for the following covariates: sex, age at onset, family history of OCD, HDRS basal score and total score on Y-BOCS. The degree of association between each SNP and the phenotype was quantified using odds ratios with 95% confidence interval. For the multiple comparison correction we considered seven independent SNPs and three different strata (all OCD patients, SLE-preceded OCD patients and non-SLE-preceded OCD patients), which gave a corrected P-value of 0.0024. For the interaction analysis of presence or absence of SLE preceding OCD with each SNP, we calculated the likelihood ratio test comparing the full interaction ordinal logistic model, which includes an interaction term SNP-SLE preceding OCD, to the simpler additive model.
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RESULTS
The final sample consisted of 124 male and 114 female OCD patients, with a mean age of 33.7 years ( ± 10.4) and a mean age at onset of 20.8 years ( ± 8.7). Of these 238 patients, 92 (38.6%) were classified as SLE-preceded probands, and 146 (61.4%) as non-SLE-preceded probands. Other clinical variables are summarized in Table 1 .
We successfully genotyped seven SNPs located in the SLC1A1 genomic region, all of them consistent with Hardy--Weinberg equilibrium (Table 2 ) and with a mean genotyping rate of 99.6%. Initial analysis of the SNP genotype frequency distributions for the SLE-preceded versus the non-SLE-preceded OCD group did not reveal significant differences with regard to demographic and clinical variables such as age, sex and OCD symptom dimensions. When we analyzed the pharmacological treatment resistance in a fully adjusted model covariating for sex, age at onset, family history of OCD and Y-BOCS and HDRS scores, three SNPs (rs301434, rs301435 and rs3087879) showed nominal associations under an additive model. In all cases, being a carrier of the variant allele increased the probability of higher treatment resistance (Table 3) . We found a significant interaction effect for each of the three SNPs in the whole OCD sample (rs301434 with P-val ¼ 0.045, rs301435 with P-val ¼ 0.041, and rs3087879 with P-val ¼ 0.031). Stratifying the sample according to the life stress-based approach, these nominal associations remained significant only in the non-SLE-preceded OCD subgroup, suggesting a stronger effect in these patients. This finding stood multiple testing correction in one SNP (rs3087879; Table 3 ). For this SNP, one copy increase of the risk allele multiplied the odds of moving from the lowest to the middle or highest resistance level (or from the lowest and middle levels to the highest level) by 2.42 (95% confidence interval ¼ 1.39--4.21).
DISCUSSION
In this study we aimed to investigate the role of variants in the SLC1A1 gene on pharmacological resistance in a sample of 238 OCD patients, and the role of their interaction with environmental factors. We found that three SNPs were associated with pharmacological resistance in the whole sample, and that this association was restricted to the subgroup of patients who did not have a SLE preceding OCD onset. These results are consistent with SLC1A1, life stress and pharmacological resistance in OCD E Real et al previous reports that our significant SNPs, namely rs301434, rs301435 and rs3087879, are associated with OCD. 13, 18 Our study adds new information to the field as it is the first to assess the interaction of glutamatergic gene variants and life stress on treatment resistance in OCD.
Disentangling which factors are involved in treatment outcome is a major challenge in OCD research. Treatment with SRIs is effective in just 40--60% of patients, 8 and the reasons why some patients achieve almost total remission of symptoms whereas other patients show minimal or no response to pharmacological trials remain unknown. The variability in treatment outcome of OCD patients reflects the high heterogeneity of the disorder. The interaction between polymorphic variations in candidate genes and clinical/environmental factors seems to underlie this high variability in treatment outcome. Some phenotypic features such as early onset, 51 higher severity 52 and the presence of hoarding symptoms 53 have been identified as predictors of poorer treatment response in OCD. With regard to the potential influence of environmental factors on the phenomenology of the disorder, in a previous study we reported that OCD patients without life stress at onset of the disorder showed more family history of OCD and higher early-onset rates. 35 These two conditions have been related to a more genetically influenced OCD, 4 and, interestingly, SLC1A1 variations have also been associated with early onset 14 and familial forms of the disorder. 15 It seems plausible that the pharmacological resistance in these patients might be more influenced by genetic background than in patients with a more environmentally influenced OCD phenotype, although this conclusion remains speculative at present.
The evidence suggests that the SLC1A1 gene is a promising candidate for OCD but studies assessing its influence on treatment outcome are lacking. Despite occasional exceptions, 19 most studies have provided positive results 13--15,17 and have replicated the association with the diagnosis of OCD, including two genomewide linkage studies. 54, 55 SLC1A1 codes for the glutamate transporter (also known as EAAC1 and EAAT3). Its dysfunction leads to prolonged activation of glutamatergic receptors, leading in turn to excitotoxic neuronal degeneration and atrophy. 56, 57 Interestingly, neuroimaging studies report associations of glutamatergic neurotransmission into OCD neuroanatomical-related structures with the prediction of severity 23 and pharmacological response 22 (for a review, see Rotge et al. 58 ). Genetic factors contribute to the general variability in drug response. 59 To date, neuropharmacological hypotheses regarding OCD pathophysiology have been strongly influenced by evidence that clomipramine and SSRIs are effective in modulating OCD symptomatology. 60, 61 Few studies have explored the pharmacogenetics of OCD, and those available focus mainly on the components of the serotonin pathway (transporter and receptors), with inconclusive results. 9, 11, 12 These and other factors, like the delay in the therapeutic benefit in the treatment of OCD, the fact that high doses of SSRIs (in excess of the typical antidepressant dose range) are often required and the benefit of augmentating therapies of standard SSRI pharmacotherapy with glutamate-modulating drugs in refractory adults, have provoked a shift in attention to other neurotransmitter systems for OCD. 62 Some authors suggest that the glutamate dysregulation reported in OCD studies supports its role into the pathophysiology of the disorder. 63 Moreover, a reciprocal interaction between serotonin and glutamate has been reported in animal research. Modulation of glutamate transmission by 5-HT has been described in several central nervous system regions, and it is known that Abbreviations: OCD, obsessive--compulsive disorder; OR, odds ratio; SLE, stressful life event; SNP, single-nucleotide polymorphism. *Statistically significant after Bonferroni correction (Po0.0024). The P-value adjusted for sex, age at onset of OCD, family history of OCD, HDRS score and total score on Y-BOCS. The P-value of interaction comparing the full interaction ordinal logistic model, which includes an interaction term SNP-SLE preceding OCD, to the simpler additive model, which includes the SNP and SLE preceding OCD as additive effects. Odds ratios derived from the ordinal logistic regression analyses under an additive inheritance model. The bold entries in this table mean significant association (Po0.05).
SLC1A1, life stress and pharmacological resistance in OCD E Real et al co-transmission of glutamate and monoamines is a very frequent phenomenon (reviewed in Ciranna 24 ). Previous work in different mental disorders has suggested a relationship between disorder risk genes and genes related to treatment response. 10, 64 It is therefore reasonable to suggest that the glutamate system, which is involved in OCD susceptibility, might also be related to (and influence) at least a small part of the phenotypic variance in the therapeutic effect of antidepressants observed in OCD patients. This new perspective complements the earlier focus on monoaminergic neurotransmission, and establishes glutamatergic neurotransmission as a promising target for OCD pharmacotherapy.
The variable representing the pharmacological resistance level was categorized in three ordinal values including different drugs or drug combinations. We opted to recode it into three clinically meaningful categories in order to reduce the level of stratification of the sample and thus facilitate data analysis. We also performed the ordinal regression analyses exploring the relationship between genetic variants, SLEs and pharmacological resistance using all resistance levels (without recoding into three categories), and the results did not change (data not shown).
In their review, Pallanti and Quercioli 46 propose a 10-level categorization of treatment resistance in which the different steps comprise various treatment strategies such as switching SRIs, antipsychotic augmentations or the use of other classes of antidepressants (like monoamine oxidase inhibitors and tricyclic antidepressants). Although not identical, the ordering of nonresponse steps in our protocol is in agreement with this concept (although it does not include neurosurgery or cognitive-behavior therapy). An issue to discuss is the role of the potential specificity of response for the particular therapeutic substance (or class of substances) included in each of these different steps. In this connection, it has been suggested that drug-specific genetic effects are of minor importance for genome-wide pharmacogenomic studies, 7 as antidepressant agents show comparable efficacy across drug classes. 65 Predictive genetic markers may be associated with neurobiologically defined final common pathways, which are common to all antidepressants. This alternative approach has been widely discussed in previous reviews 66 and in earlier reports by our group. 10 On the other hand, our variants are intronic and may have no functional consequence; they may be in linkage disequilibrium with a nearby but as yet unidentified functional polymorphism. Further sequencing studies covering the whole region are needed to answer this question.
Our findings should be considered in the light of certain limitations. One is the possible source of bias potentially associated with self-reported recollections of data, such as previous pharmacological treatments received. We did not follow the patients from the naive state and cannot be sure that they completed the time and dosages corresponding to each of our treatment resistance levels. In order to address this issue we performed a face-to-face interview during which we carefully enquired about previous adequate medication trials and asked for prescriptions and medical reports when available. We also used accepted operational criteria for variables of treatment response. As our unit is a referral center for OCD patients, our sample may present a higher-than-average degree of severity and the results may not be generalizable to all patients in the community. On the other hand, our study includes some methodological strengths, such as the use of interview-based methods to assess life events at onset of the disorder. These are considered the gold standard for evaluating life stress, 67 and we also used an established conventional list to refer to life events (the Paykel list).
In summary, our results support the hypothesis that OCD candidate genes such as SLC1A1 have an important role in measurements of pharmacological response. We found a positive association between variants of the glutamate transporter gene and pharmacological resistance in OCD. This association was moderated by the presence of life stress at onset of the disorder, as it remained significant only in probands without SLE preceding OCD onset. This supports a gene-by-environment interaction effect and strengthens the existing evidence of the role of glutamatergic system and environmental factors in the phenomenology of OCD. Additional research is needed to replicate these findings of gene-by-environment interaction.
